Surmodics, Inc. (SRDX)

Surmodics Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Year	2023	2022	2021	2020	2019
Net Income	-1.54	-27.27	4.24	1.12	7.59
Depreciation & Amortization	9.17	9.67	8.33	7.51	7.31
Share-Based Compensation	7.61	7.06	5.86	5.45	5.08
Other Operating Activities	-4.73	-6.68	-3.04	-0.08	-11.94
Operating Cash Flow	10.51	-17.22	15.39	14.01	8.04
Operating Cash Flow Growth	-	-	9.84%	74.30%	-76.39%
Capital Expenditures	-2.92	-3.37	-5.28	-3.67	-6
Acquisitions	0	0	-40.55	0	0
Change in Investments	-3.9	9.6	20.59	-5.4	16.49
Other Investing Activities	-	-	-	-	-0.73
Investing Cash Flow	-6.82	6.23	-25.24	-9.07	9.75
Share Issuance / Repurchase	1.25	1.25	3.13	1.62	0.72
Debt Issued / Paid	19.05	0	10	-0.14	0
Other Financing Activities	-1.9	-1.62	-2.9	-6.13	-11.75
Financing Cash Flow	18.41	-0.38	10.23	-4.65	-11.03
Exchange Rate Effect	0.32	-0.79	-0.01	0.13	-0.07
Net Cash Flow	22.42	-12.16	0.37	0.42	6.69
Free Cash Flow	7.6	-20.59	10.11	10.34	2.04
Free Cash Flow Growth	-	-	-2.21%	406.81%	-91.83%
Free Cash Flow Margin	5.73%	-20.60%	9.62%	10.90%	2.04%
Free Cash Flow Per Share	0.54	-1.48	0.73	0.76	0.15

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).